Search

KR-20260062181-A - Limosilactobacillus fermentum SLAM216 strain, its extracellular vesicles, and their anti-inflammatory use

KR20260062181AKR 20260062181 AKR20260062181 AKR 20260062181AKR-20260062181-A

Abstract

The present invention relates to the Limosi Lactobacillus fermentum SLAM216 strain, its extracellular vesicles, and its anti-inflammatory uses. According to one aspect of the present invention, a composition comprising the Limosi Lactobacillus fermentum SLAM216 strain or the extracellular vesicles of said strain can be usefully utilized for the prevention or treatment of skin inflammation such as atopic dermatitis.

Inventors

  • 김영훈
  • 최혜진

Assignees

  • 서울대학교산학협력단

Dates

Publication Date
20260507
Application Date
20241025

Claims (11)

  1. Limosilactobacillus fermentum strain SLAM216, deposited under accession number KACC 81307BP.
  2. Claim 1, wherein the strain comprises the 16S rRNA of Sequence No. 1.
  3. Extracellular vesicle derived from the strain of claim 1.
  4. An anti-inflammatory composition comprising one or more selected from the group consisting of the strain of claim 1 or 2, extracellular vesicles derived from said strain, dried product, lysate, lysate, culture medium of said strain, extracts thereof, and fractions of the extract.
  5. In claim 4, the composition is (i) inhibit the production of inflammatory cytokines, or (ii) increasing one or more intestinal metabolites selected from the group consisting of glycine, l-proline, lactic acid, alanine, fumaric acid, lactulose, maltose, soyasapogenol B, leucine, isoleucine, valine, or inosine, or (iii) An anti-inflammatory composition that increases serotonin secretion.
  6. A pharmaceutical composition for preventing or treating skin inflammation, comprising one or more selected from the group consisting of the strain of claim 1 or 2, extracellular vesicles derived from said strain, dried product, lysate, lysate, culture medium of said strain, extracts thereof, and fractions of the extract.
  7. A pharmaceutical composition according to claim 6, wherein the skin inflammation comprises one or more selected from the group consisting of allergic dermatitis, irritant dermatitis, seborrheic dermatitis, atopic dermatitis, inflammatory skin aging, pruritus, dry eczema, erythema, urticaria, psoriasis, drug rash, and acne.
  8. A cosmetic composition for preventing or improving skin inflammation, comprising one or more selected from the group consisting of the strain of claim 1 or 2, extracellular vesicles derived from said strain, dried product, lysed product, lysate, culture medium of said strain, extracts thereof, and fractions of the extract.
  9. A cosmetic composition according to claim 8, wherein the skin inflammation comprises one or more selected from the group consisting of allergic dermatitis, irritant dermatitis, seborrheic dermatitis, atopic dermatitis, inflammatory skin aging, pruritus, dry eczema, erythema, urticaria, psoriasis, drug rash, and acne.
  10. A health functional food for preventing or improving skin inflammation, comprising one or more selected from the group consisting of the strain of claim 1 or 2, extracellular vesicles derived from said strain, dried product, crushed product, lysate, culture medium of said strain, extracts thereof, and fractions of the extract.
  11. A health functional food for improving gut health, comprising one or more selected from the group consisting of the strain of claim 1 or 2, extracellular vesicles derived from said strain, dried product, crushed product, lysate, culture medium of said strain, extracts thereof, and fractions of the extract.

Description

Limosilactobacillus fermentum SLAM216 strain, its extracellular vesicles, and their anti-inflammatory use This relates to the Limosi Lactobacillus fermentum SLAM216 strain, its extracellular vesicles, and its anti-inflammatory uses. Atopic dermatitis (AD) is a chronic inflammatory skin disease that can affect both children and adults. Although the pathogenesis of AD has not yet been clearly elucidated, several studies have suggested that genetic predisposition, abnormal immune responses, environmental factors, and impaired epidermal function may interact to contribute to its development. In particular, the occurrence of AD in children may increase the risk of allergic diseases such as asthma, rhinitis, and food allergies. Furthermore, scratching the skin due to itching caused by AD damages the skin barrier, which can impair sleep quality and adversely affect growth and development. Currently, topical steroids and systemic immunosuppressants are primarily used to treat AD; however, there is a lack of long-term safety data in children, and the use of systemic drugs carries risks of side effects and recurrence after discontinuation of treatment. Therefore, there is a need to develop new treatments with fewer side effects (Non-patent Literature 0001). Recent studies have revealed an association between the gut microbiome and the onset of AD. Changes in the gut microbiome can affect various physiological processes, such as metabolism, immunity, and development; based on this, therapeutic strategies utilizing probiotics and metabolites to alleviate AD symptoms by regulating the gut microbiome are receiving attention. In this context, methods to alter the composition of the gut microbiome are considered a promising approach for the treatment of AD (Non-patent Literature 0002). Extracellular vesicles (EVs) are nano-sized structures that transport bioactive substances such as proteins, lipids, and nucleic acids, and can play a significant role in host pathophysiological processes. In particular, EVs are surrounded by a lipid bilayer, allowing them to pass through various tissues, blood vessels, and mucosal layers, and efficiently deliver bioactive substances to induce potent cellular responses. Recently, EVs have garnered attention as a means to deliver the effects of probiotics more safely and efficiently, and are emerging as a method to minimize side effects even in vulnerable patients for whom the use of probiotics may be contraindicated. In particular, probiotic-derived EVs are attracting attention as novel therapeutic agents, and some studies have demonstrated that EVs can alleviate gastrointestinal disorders or improve stress-induced behaviors by regulating specific pathways. These studies suggest the potential of EVs as a next-generation alternative to probiotics (Non-patent Literature 0003). Accordingly, the inventors of the present application intend to develop and provide a substance for the improvement, prevention, or treatment of diseases using novel intestinal microorganisms and extracellular vesicles derived therefrom. Figure 1 is an SEM image of LF216 and LF216EV. Figure 2 is a TEM image of LF216EV particles derived from LF216. Figure 3 is a graph of the NTA analysis results showing the particle range of LF216EV. Figure 4 is a Venn diagram of the proteomic profiling analysis results of LF216 and LF216EV. Figure 5 is a graph regarding the functional classification of LF216EV proteins identified according to cellular components, molecular functions, and biological processes. Figure 6 is a graph of the results of gene ontology (GO) analysis for the LF216EV protein. Figure 7 is a graph of the lipid profile analysis results of LF216 and LF216EV. Figure 8 is a graph showing the results of a comparative analysis of the lipid profiles between LF216 and LF216EV. Figure 9 is a graph showing the relative comparison results of lipid content between LF216 and LF216EV. Figure 10 is an overview of metabolite profiling of LF216 and LF216EV using a heatmap. Figure 11 is a graph showing the results of comparing fatty acid classes between LF216 and LF216EV. Figure 12 is a graph of the results of the KEGG metabolic pathway analysis related to metabolites that differ significantly in LF216EV. Figure 13 is a graph of the survival rates of C. elegans CF512 fer-15(b26)II;fem-1(hc17) IV(fer-15;fem-1, S. aureus Newman, and E. coli O157 after 24 hours of pre-conditioning with LF216 and LF216EV. Figure 14 is a graph showing that LF216EV induces the expression of the pmk-1 gene in C. elegans . Figure 15 is a graph of the changes in length and width of C. elegans after administration of LF216 and LF216EV. Figure 16 is an image confirming the wound healing effect of LF216EV in HaCaT cells. Figure 17 is a graph confirming the wound healing effect of LF216EV in HaCaT cells. Figure 18 is a graph showing the effect of LF216EV on cytokine expression in HaCaT cells. Figure 19 is a schematic diagram of an experiment to confirm that LF216E